

as per Annex IV of the Regulation EU 2017/746 on in-vitro diagnostic medical devices

Manufacturer:Roche Diagnostics GmbHAddress:Sandhofer Strasse 116

68305 Mannheim

Germany

Single Registration Number: DE-MF-000006260

Roche Diagnostics GmbH declares, under the sole responsibility, that the product/the product line

Product Name	Cat. No.	Basic UDI-DI
Elecsys CA 125 II	11776223190	7613336001369X
Elecsys CA 125 II	11776223214	761333602082AF

### Intended Use:

Immunoassay for the in vitro quantitative determination of OC 125 reactive determinants in human serum and plasma. These determinants are associated with a high molecular weight glycoprotein in serum and plasma of women with primary epithelial invasive ovarian cancer (excluding those with cancer of low malignant potential). This assay is indicated for use as an aid in the detection of residual or recurrent ovarian carcinoma in patients who have undergone first-line therapy and would be considered for second-look procedures. This assay is further indicated for serial measurement of CA 125 to aid in the management of cancer patients. This assay is also intended to be used in conjunction with the Elecsys HE4 assay as part of ROMA (Risk Of Ovarian Malignancy Algorithm) for the risk assessment of ovarian cancer in premenopausal and postmenopausal women presenting with pelvic mass.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on Elecsys and cobas e immunoassay analyzers.

Product Name	Cat. No.	Basic UDI-DI
Elecsys CA 125 II	07026986190	761333600245A5
Elecsys CA 125 II	07026986214	761333602048AF

### Intended Use:

Immunoassay for the in vitro quantitative determination of OC 125 reactive determinants in human serum and plasma. These determinants are associated with a high molecular weight glycoprotein in serum and plasma of women with primary epithelial invasive ovarian cancer (excluding those with cancer of low malignant potential). This assay is indicated for use as an aid in the detection of residual or recurrent ovarian carcinoma in patients who have undergone first-line therapy and would be considered for second-look procedures. This assay is further indicated for serial measurement of CA 125 to aid in the management of cancer patients. This assay is also intended to be used in conjunction with the Elecsys HE4 assay as part of ROMA (Risk Of Ovarian Malignancy Algorithm) for the risk assessment of ovarian cancer in pre- and postmenopausal women presenting with pelvic mass. The electrochemiluminescence immunoassay "ECLIA" is intended for use on cobas e immunoassay analyzers.



Product Name	Cat. No.	Basic UDI-DI
CA 125 II CalSet II	07030207190	761333600406A5

### Intended Use:

CA 125 II CalSet II is used for calibrating the quantitative Elecsys CA 125 II assay on cobas e immunoassay analyzers.

Risk Class:	$\square A \square B \boxtimes C \square D$
Conformity Route:	□ Self-Declaration of Conformity (Class A) □ Self-Declaration of Conformity after Notified Body involvement for sterile manufacturing conditions acc. Art. 48 (10) (Class A sterile) □ Technical Documentation Assessment Class B/C – Annex IX □ Technical Documentation Assessment Class B/C/D for Self-Testing – Annex IX □ Technical Documentation Assessment Class B/C/D for Near-Patient Testing – Annex IX □ Technical Documentation Assessment Class C/D for Companion Diagnostics – Annex IX
Certificates:	<ul> <li>         ∑ EU QM Certificate No.: V12 010283 0639          ☐ EU Technical Documentation Assessment Certificate No.      </li> <li>(Class D, Near-Patient Testing, Self-Testing and Companion Diagnostics):</li> </ul>
Other:	Common Specifications:
Notified Body (NB) Name: NB Address: NB Ident. No.:	TÜV Süd Product Service GmbH Ridlerstraβe 65 80339 Munich Germany 0123
to which this declaration relates fulfi medical devices.	ils the requirements of Regulation EU 2017/746 on in-vitro diagnostic
Mannheim, 30 March 2023	
Roche Diagnostics GmbH	
i.V./on behalf of the company	ppa./on behalf of the company
Docusigned by: Christina Schmid E3965E80F3E840E	Stefan Schuib FC5EDEC1054B44C
Dr. Christina Schmid Head of Pre-Market Quality Core La	Dr. Stefan Scheib  Global Head of Regulatory Affairs, Core Lab
	coche Diagnostics GmbH abt./Dept. Global Regulatory Affairs

Sandhofer Strasse 116 D-68305 Mannheim



as per Annex IV of the Regulation EU 2017/746 on in-vitro diagnostic medical devices

Manufacturer:Roche Diagnostics GmbHAddress:Sandhofer Strasse 116

68305 Mannheim

Germany

Single Registration Number: DE-MF-000006260

Roche Diagnostics GmbH declares, under the sole responsibility, that the product/the product line

Product Name	Cat. No.	Basic UDI-DI
Elecsys CA 19-9	11776193122	761333600730AH
Elecsys CA 19-9	11776193214	761333602081AD

### Intended Use:

Immunoassay for the in vitro quantitative determination of CA 19-9 in human serum and plasma.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on Elecsys and cobas e immunoassay analyzers

Product Name	Cat. No.	Basic UDI-DI
Elecsys CA 19-9	07027028190	761333600799BM
Elecsys CA 19-9	07027028214	761333602050A2

### Intended Use:

Immunoassay for the in vitro quantitative determination of CA 19-9 in human serum and plasma.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on cobas e immunoassay analyzers.

Product Name	Cat. No.	Basic UDI-DI
CA 19-9 CalSet	11776215122	761333600732AM

## Intended Use:

CA 19-9 CalSet is used for calibrating the quantitative Elecsys CA 19-9 assay on cobas e immunoassay analyzers.

Risk Class:	1 4		מו	abla	C	$\Box$	ח
NISK CIUSS.	Α	ı	D	M		ıı	$\nu$



Conformity Route:	□ Self-Declaration of Conformity (Class A) □ Self-Declaration of Conformity after Notified Body involvement for sterile manufacturing conditions acc. Art. 48 (10) (Class A sterile) □ Technical Documentation Assessment Class B/C – Annex IX □ Technical Documentation Assessment Class B/C/D for Self-Testing – Annex IX □ Technical Documentation Assessment Class B/C/D for Near-Patient Testing – Annex IX □ Technical Documentation Assessment Class C/D for Companion Diagnostics – Annex IX
Certificates:	<ul> <li>         ⊠ EU QM Certificate No.: V12 010283 0639          □ EU Technical Documentation Assessment Certificate No.     </li> <li>(Class D, Near-Patient Testing, Self-Testing and Companion Diagnostics):</li> </ul>
Other:	☐ Common Specifications:
Notified Body (NB) Name: NB Address:	TÜV Süd Product Service GmbH Ridlerstraße 65 80339 Munich Germany
NB Ident. No.:	0123
to which this declaration relates fulfi medical devices.	ils the requirements of Regulation EU 2017/746 on in-vitro diagnostic
Mannheim, 15 March 2023	
Roche Diagnostics GmbH	
i.V./on behalf of the company	ppa./on behalf of the company
Christina Schmid	Stefan Scheib FCSEDEC1054B44C
Dr. Christina Schmid Head of Pre-Market Quality Core La	Dr. Stefan Scheib  Global Head of Regulatory Affairs, Core Lab
A S	Roche Diagnostics GmbH Abt./Dept. Global Regulatory Affairs andhofer Strasse 116 D-68305 Mannheim



as per Annex IV of the Regulation EU 2017/746 on in-vitro diagnostic medical devices

Manufacturer:Roche Diagnostics GmbHAddress:Sandhofer Strasse 116

68305 Mannheim

Germany

Single Registration Number: DE-MF-000006260

Roche Diagnostics GmbH declares, under the sole responsibility, that the product/the product line

Product Name	Cat. No.	Basic UDI-DI
Elecsys Anti-CCP	05031656190	761333600952B5

### Intended Use:

Immunoassay for the in vitro semi-quantitative determination of human IgG autoantibodies to cyclic citrullinated peptides in human serum. The results of the assay are intended to be used as an aid in the diagnosis of rheumatoid arthritis in combination with other clinical and laboratory findings.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on Elecsys and cobas e immunoassay analyzers.

Product Name	Cat. No.	Basic UDI-DI
PreciControl Anti-CCP	05031664190	761333600953B7

### Intended Use:

PreciControl Anti-CCP is used for quality control of the Elecsys Anti-CCP immunoassay on cobas e immunoassay analyzers.

Product Name	Cat. No.	Basic UDI-DI
Elecsys Anti-CCP	07251670190	761333600999BX

### Intended Use:

Immunoassay for the in vitro semi-quantitative determination of human IgG autoantibodies to cyclic citrullinated peptides in human serum. The results of the assay are intended to be used as an aid in the diagnosis of rheumatoid arthritis in combination with other clinical and laboratory findings.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on cobas e immunoassay analyzers.



Risk Class:	$\square A \boxtimes B \square C \square D$
Conformity Route:	□ Self-Declaration of Conformity (Class A) □ Self-Declaration of Conformity after Notified Body involvement for sterile manufacturing conditions acc. Art. 48 (10) (Class A sterile) □ Technical Documentation Assessment Class B/C – Annex IX □ Technical Documentation Assessment Class B/C/D for Self-Testing – Annex IX □ Technical Documentation Assessment Class B/C/D for Near-Patient Testing – Annex IX □ Technical Documentation Assessment Class C/D for Companion Diagnostics – Annex IX
Certificates:	<ul> <li>         ⊠ EU QM Certificate No.: V12 010283 0639          □ EU Technical Documentation Assessment Certificate No.         (Class D, Near-Patient Testing, Self-Testing and Companion Diagnostics):     </li> </ul>
Other:	Common Specifications:
Notified Body (NB) Name: NB Address:	TÜV Süd Product Service GmbH Ridlerstraße 65 80339 Munich Germany
NB Ident. No.:	0123
to which this declaration relates ful medical devices.	fils the requirements of Regulation EU 2017/746 on in-vitro diagnostic
Mannheim, 26 April 2023	
Roche Diagnostics GmbH	
i.V./on behalf of the company	ppa./on behalf of the company
Docusigned by: Christina Schmid E3965E80F3E840E	Stefan Scheib FCSEDEC1054B44C
Dr. Christina Schmid Head of Pre-Market Quality Core L	Dr. Stefan Scheib  Global Head of Regulatory Affairs, Core Lab
	Roche Diagnostics GmbH Abt./Dept. Global Regulatory Affairs Sandhofer Strasse 116 D-68305 Mannheim



as per Annex IV of the Regulation EU 2017/746 on in-vitro diagnostic medical devices

Manufacturer:Roche Diagnostics GmbHAddress:Sandhofer Strasse 116

68305 Mannheim

Germany

Single Registration Number: DE-MF-000006260

Roche Diagnostics GmbH declares, under the sole responsibility, that the product/the product line

Product Name	Cat. No.	Basic UDI-DI
Elecsys CEA	11731629322	7613336001349T

### Intended Use:

Immunoassay for the in vitro quantitative determination of carcinoembryonic antigen in human serum and plasma. This assay is further indicated for serial measurement of CEA to aid in the management of cancer patients.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on Elecsys and cobas e immunoassay analyzers.

.

Product Name	Cat. No.	Basic UDI-DI
Elecsys CEA	07027079190	761333600248AB
Elecsys CEA	07027079214	761333602051A4

### Intended Use:

Immunoassay for the in vitro quantitative determination of carcinoembryonic antigen in human serum and plasma. This assay is further indicated for serial measurement of CEA to aid in the management of cancer patients.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on cobas e immunoassay analyzers.

Product Name	Cat. No.	Basic UDI-DI
Elecsys CEA	04491777190	761333600279AN

### Intended Use:

Immunoassay for the in vitro quantitative determination of carcinoembryonic antigen in human serum and plasma. This assay is further indicated for serial measurement of CEA to aid in the management of cancer patients.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on MODULAR ANALYTICS E170, cobas e 601 and cobas e 602 immunoassay analyzers.

<b>Product Name</b>	Cat. No.	Basic UDI-DI
CEA CalSet	11731645322	7613336001359V

### Intended Use:

CEA CalSet is used for calibrating the quantitative Elecsys CEA assay on cobas e immunoassay analyzers.



Risk Class:	$\square A \square B \boxtimes C \square D$
Conformity Route:	□ Self-Declaration of Conformity (Class A) □ Self-Declaration of Conformity after Notified Body involvement for sterile manufacturing conditions acc. Art. 48 (10) (Class A sterile) □ Technical Documentation Assessment Class B/C – Annex IX □ Technical Documentation Assessment Class B/C/D for Self-Testing – Annex IX □ Technical Documentation Assessment Class B/C/D for Near-Patient Testing – Annex IX □ Technical Documentation Assessment Class C/D for Companion Diagnostics – Annex IX
Certificates:	<ul> <li>         ∑ EU QM Certificate No.: V12 010283 0639          ☐ EU Technical Documentation Assessment Certificate No.         (Class D, Near-Patient Testing, Self-Testing and Companion Diagnostics):     </li> </ul>
Other:	☐ Common Specifications:
Notified Body (NB) Name: NB Address:	TÜV Süd Product Service GmbH Ridlerstraβe 65 80339 Munich
NB Ident. No.:	Germany 0123
to which this declaration relates fu medical devices.	lfils the requirements of Regulation EU 2017/746 on in-vitro diagnostic
Mannheim, 14 November 2022	
Roche Diagnostics GmbH	
i.V./on behalf of the company  Docusigned by:  Liristina Schmid  59311CC1CDA8480  Dr. Christina Schmid  Head of Pre-Market Quality Core I	ppa./on behalf of the company  DocuSigned by:  Stefan Scheil  FC5EDEC1054B44C  Dr. Stefan Scheib  Global Head of Regulatory Affairs, Core Lab
Contact address:	Roche Diagnostics GmbH Abt./Dept. Global Regulatory Affairs Sandhofer Strasse 116 D-68305 Mannheim



as per Annex IV of the Regulation EU 2017/746 on in-vitro diagnostic medical devices

Manufacturer:Roche Diagnostics GmbHAddress:Sandhofer Strasse 11668305 Mannheim

Germany

Single Registration Number: DE-MF-000006260

Roche Diagnostics GmbH declares, under the sole responsibility, that the product/the product line

Product Name	Cat. No.	Basic UDI-DI
CleanCell	11662970122	761333601644AW

### Intended Use:

System solution for cleaning the detection unit of the cobas e 411 immunoassay analyzer. CleanCell is used in conjunction with Elecsys assay reagents. CleanCell can be used with all reagent lots.

Risk Class:	$\boxtimes A \square B \square C \square D$
Conformity Route:	Self-Declaration of Conformity (Class A)  Self-Declaration of Conformity after Notified Body involvement for sterile manufacturing conditions acc. Art. 48 (10) (Class A sterile)  Technical Documentation Assessment Class B/C − Annex IX  Technical Documentation Assessment Class B/C/D for Self-Testing − Annex IX  Technical Documentation Assessment Class B/C/D for Near-Patient Testing − Annex IX  Technical Documentation Assessment Class B/C/D for Companion Diagnostics − Annex IX
Certificates:	☐ EU QM Certificate No.: ☐ EU Technical Documentation Assessment Certificate No. (Class D, Near-Patient Testing, Self-Testing and Companion Diagnostics):
Other:	☐ Common Specifications:
Notified Body (NB) Name: NB Address:	N/A
NB Ident. No.:	N/A
to which this declaration relates medical devices.	fulfils the requirements of Regulation EU 2017/746 on in-vitro diagnostic



Mannheim, 16 June 2023

Roche Diagnostics GmbH

i.V./on behalf of the company

DocuSigned by:

Christina Schmid

Dr. Christina Schmid

Head of Pre-Market Quality Core Lab

ppa./on behalf of the company

-DocuSigned by:

Stefan Scheib FCSEDEC1054B44C...

Dr. Stefan Scheib

Global Head of Regulatory Affairs, Core Lab

Contact address: Roche Diagnostics GmbH

Abt./Dept. Global Regulatory Affairs

Sandhofer Strasse 116 D-68305 Mannheim



as per Annex IV of the Regulation EU 2017/746 on in-vitro diagnostic medical devices

Manufacturer:Roche Diagnostics GmbHAddress:Sandhofer Strasse 116

68305 Mannheim

Germany

Single Registration Number: DE-MF-000006260

Roche Diagnostics GmbH declares, under the sole responsibility, that the product/the product line

Product Name	Cat. No.	Basic UDI-DI
Elecsys Cortisol	11875116122	761333600740AL

### Intended Use:

Immunoassay for the in vitro quantitative determination of cortisol in human serum, plasma, urine, and saliva. The determination of cortisol is used for the recognition and treatment of functional disorders of the adrenal gland.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on Elecsys and cobas e immunoassay analyzers.

Product Name	Cat. No.	Basic UDI-DI
Cortisol CalSet	11875124122	761333600741AN

### Intended Use:

Cortisol CalSet is used for calibrating the quantitative Elecsys Cortisol assay on the Elecsys and cobas e immunoassay analyzers.

Risk Class:	$\square A \boxtimes B \square C \square D$
Conformity Route:	☐ Self-Declaration of Conformity (Class A) ☐ Self-Declaration of Conformity after Notified Body involvement for sterile manufacturing conditions acc. Art. 48 (10) (Class A sterile) ☐ Technical Documentation Assessment Class B/C – Annex IX ☐ Technical Documentation Assessment Class B/C/D for Self-Testing
	<ul> <li>Annex IX</li> <li>☐ Technical Documentation Assessment Class B/C/D for Near-Patient Testing – Annex IX</li> <li>☐ Technical Documentation Assessment Class C/D for Companion Diagnostics – Annex IX</li> </ul>



Certificates: ⊠ EU QM Certificate No.: V12 010283 0639 ☐ EU Technical Documentation Assessment Certificate No. (Class D, Near-Patient Testing, Self-Testing and Companion Diagnostics): ☐ Common Specifications: Other: Notified Body (NB) Name: TÜV Süd Product Service GmbH NB Address: Ridlerstraße 65 80339 Munich Germany 0123 NB Ident. No.: to which this declaration relates fulfils the requirements of Regulation EU 2017/746 on in-vitro diagnostic medical devices. Mannheim, 26 April 2023 Roche Diagnostics GmbH i.V./on behalf of the company ppa./on behalf of the company DocuSigned by: DocuSigned by: Christina Schmid Stefan Scheib E3965E80F3E840E... Dr. Christina Schmid Dr. Stefan Scheib Global Head of Regulatory Affairs, Core Lab Head of Pre-Market Quality Core Lab Contact address: Roche Diagnostics GmbH Abt./Dept. Global Regulatory Affairs

Sandhofer Strasse 116 D-68305 Mannheim



as per Annex IV of the Regulation EU 2017/746 on in-vitro diagnostic medical devices

Manufacturer:Roche Diagnostics GmbHAddress:Sandhofer Strasse 116

68305 Mannheim

Germany

Single Registration Number: DE-MF-000006260

Roche Diagnostics GmbH declares, under the sole responsibility, that the product/the product line

Product Name	Cat. No.	Basic UDI-DI
Elecsys C-Peptide	03184897190	761333600931AV
Elecsys C-Peptide	03184897214	761333602044A7

### Intended Use:

Immunoassay for the in vitro quantitative determination of C-peptide in human serum, plasma and urine. The assay is intended for use as an aid in the diagnosis and treatment of patients with abnormal insulin secretion. The electrochemiluminescence immunoassay "ECLIA" is intended for use on Elecsys and cobas e immunoassay analyzers.

Product Name	Cat. No.	Basic UDI-DI
Elecsys C-Peptide	07027168190	761333600993BK
Elecsys C-Peptide	07027168214	761333602053A8

### Intended Use:

Immunoassay for the in vitro quantitative determination of C-peptide in human serum, plasma and urine. The assay is intended for use as an aid in the diagnosis and treatment of patients with abnormal insulin secretion. The electrochemiluminescence immunoassay "ECLIA" is intended for use on cobas e immunoassay analyzers.

Product Name	Cat. No.	Basic UDI-DI
C-Peptide CalSet	03184919190	761333600932AX

## Intended Use:

C-Peptide CalSet is used for calibrating the quantitative Elecsys C-Peptide assay on cobas e immunoassay analyzers.

Risk Class:	$\Box A$	$\boxtimes$	В	П	C	D



Conformity Route:	Self-Declaration of Co			
		onformity after Notified Body involvement for		
		aditions acc. Art. 48 (10) (Class A sterile)		
		tion Assessment Class B/C – Annex IX		
	<del></del>	tion Assessment Class D – Annex IX		
	☐ Technical Documenta – Annex IX	tion Assessment Class B/C/D for Self-Testing		
		tion Assessment Class B/C/D for Near-Patient		
	Testing – Annex IX	won Historian Chass B/C/D for Iveal I allem		
		tion Assessment Class C/D for Companion		
	Diagnostics – Annex IX			
Certificates:	⊠ EU QM Certificate No	⊠ EU QM Certificate No.: V12 010283 0639		
•		☐ EU Technical Documentation Assessment Certificate No.		
		esting, Self-Testing and Companion		
	Diagnostics):			
Other:	Common Specification	as:		
Notified Body (NB) Name:	TÜV Süd Product Service	GmbH		
NB Address:	Ridlerstraße 65			
112 11001 0001	80339 Munich	· ·		
	Germany			
NB Ident. No.:	0123			
to which this declaration relates medical devices.	fulfils the requirements of Regu	ulation EU 2017/746 on in-vitro diagnostic		
Mannheim, 30 March 2023				
Roche Diagnostics GmbH				
i.V./on behalf of the company	ppa./on	behalf of the company		
DocuSigned by:	Do	cuSigned by:		
Christina Schmid	C+,	Fam Schriff		
E3965E80F3E840E	FC	5EDEC1054B44C		
Dr. Christina Schmid	Dr. Ste	fan Scheib		
Head of Pre-Market Quality Cor		Head of Regulatory Affairs, Core Lab		
Contact address:	Roche Diagnostics GmbH			
		Abt./Dept. Global Regulatory Affairs		
	Sandhofer Strasse 116			
	D-68305 Mannheim			

2/2



as per Annex IV of the Regulation EU 2017/746 on in-vitro diagnostic medical devices

Manufacturer:Roche Diagnostics GmbHAddress:Sandhofer Strasse 116

68305 Mannheim

Germany

Single Registration Number: DE-MF-000006260

Roche Diagnostics GmbH declares, under the sole responsibility, that the product/the product line

Product Name	Cat. No.	Basic UDI-DI
Elecsys DHEA-S	03000087122	761333600572AP

### Intended Use:

Immunoassay for the in vitro quantitative determination of dehydroepiandrosterone sulfate (DHEA-S) in human serum and plasma.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on Elecsys and cobas e immunoassay analyzers.

Product Name	Cat. No.	Basic UDI-DI
Elecsys DHEA-S	07027192190	761333600801AF

### Intended Use:

Immunoassay for the in vitro quantitative determination of dehydroepiandrosterone sulfate (DHEA-S) in human serum and plasma.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on cobas e immunoassay analyzers.

Product Name	Cat. No.	Basic UDI-DI
DHEA-S CalSet	03000095122	761333600573AR

### Intended Use:

Intended use DHEA-S CalSet is used for calibrating the quantitative Elecsys DHEA-S assay on cobas e immunoassay analyzers.



Risk Class:	$\bigsqcup A \boxtimes B \bigsqcup C \bigsqcup D$	
Conformity Route:	□ Self-Declaration of Conformity (Class A) □ Self-Declaration of Conformity after Notified Body involvement for sterile manufacturing conditions acc. Art. 48 (10) (Class A sterile) □ Technical Documentation Assessment Class B/C – Annex IX □ Technical Documentation Assessment Class D – Annex IX □ Technical Documentation Assessment Class B/C/D for Self-Testing – Annex IX □ Technical Documentation Assessment Class B/C/D for Near-Patien Testing – Annex IX □ Technical Documentation Assessment Class C/D for Companion Diagnostics – Annex IX	3
Certificates:	<ul> <li>EU QM Certificate No.: V12 010283 0639</li> <li>■ EU Technical Documentation Assessment Certificate No.</li> <li>(Class D, Near-Patient Testing, Self-Testing and Companion Diagnostics):</li> </ul>	
Other:	Common Specifications:	
Notified Body (NB) Name: NB Address:	TÜV Süd Product Service GmbH Ridlerstraße 65 80339 Munich Germany	
NB Ident. No.:	0123	
to which this declaration relat medical devices.	es fulfils the requirements of Regulation EU 2017/746 on in-vitro diagnostic	
Mannheim, 15 March 2023		
Roche Diagnostics GmbH		
i.V./on behalf of the company	ppa./on behalf of the company	
Docusigned by: Christina Schmid E3965E80F3E840E	Stefan Schuib FC5EDEC1054B44C	
Dr. Christina Schmid Head of Pre-Market Quality C	Dr. Stefan Scheib  Ore Lab  Global Head of Regulatory Affairs, Core Lab	
Contact address:	Roche Diagnostics GmbH Abt./Dept. Global Regulatory Affairs Sandhofer Strasse 116 D-68305 Mannheim	



# EG-Konformitätserklärung/EC Declaration of Conformity

gemäß Anhang III der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 as per Annex III of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998

Hersteller/Manufacturer:

Roche Diagnostics GmbH

Adresse/Address:

Roche Professional Diagnostics

Sandhofer Straße 116 D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie (bei rezepturgleichen Produkten) Roche Diagnostics GmbH declares that the product/the product line (in case of products manufactured by identical recipes)

Produktname/Product name:

**Diluent Universal** 

Art.-Nr./Id. No.:

11732277

Beschreibung/Description:

Diluent Universal dient als Verdünnungsmedium für Proben in Verbindung mit

Elecsys Test-Reagenzien.

Diluent Universal is used as a sample diluent in conjunction with Elecsys assay

reagents.

auf das/die sich diese Erklärung bezieht, den Forderungen der EG-Richtlinie 98/79/EG des Rates vom 27. Oktober 1998 (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) über In-vitro-Diagnostica entspricht.

to which this declaration relates fulfils the requirements of EC Directive 98/79/EC of the Council of 27 October 1998 (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market) concerning in-vitro diagnostic devices.

Mannheim, 19.07.2013 Roche Diagnostics GmbH

ppa./on behalf of the company

i. V. Ion behalf of the company

Dr. M. Thein

Head of Quality

Roche Professional Diagnostics

Dr. C. Fleischer

Head of Quality Control Penzberg Roche Diagnostics Global Operations

Kontaktadresse/Contact address:

Roche Professional Diagnostics

Abt./Dept. Global Regulatory Affairs

Sandhofer Straße 116 D-68305 Mannheim Fax: +49 621/759 1448

11732277\_Diluent Universal - la

1/1

**Roche Diagnostics GmbH** 

Diagnostics Division

Roche Diagnostics GmbH; Werk Penzberg; Nonnenwald 2; D 82377 Penzberg; Telefon +49 8856 60 0; Telefax +49 8856 60 3896

Sitz der Gesellschaft: Mannheim - Registergericht: AG Mannheim HRB 3962 - Geschäftsführung: Thomas Schmid, Sprecher: Edgar Vieth - Aufsichtsratsvorsitzender: Dr. Severin Schwan